{"filing":{"accession_number":"0001493152-26-037231","cik":"0001290877","ticker":null,"company_name":"Clinuvel Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1290877/000149315226037231/form6-k.htm"},"events":[{"id":26977,"run_id":24542,"accession_number":"0001493152-26-037231","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"CLINUVEL announced advancement of its VLRX-L controlled-release injectable peptide platform following promising preclinical results, with candidate formulations selected for further preclinical studies in Q1 2027 and manufacturing scale-up being scoped. This is a material operational/R\u0026D milestone disclosing progress on a key platform technology, but does not fit discrete event categories (not an earnings release, M\u0026A, impairment, or litigation); it is a strategic product-development update that would affect investor assessment of the company's pipeline and technical capabilities.","company_name":"Clinuvel Pharmaceuticals Ltd","ticker":null,"filing_date":"2026-08-12","form":"6-K","submitted_at":null,"items":[{"id":28292,"accession_number":"0001493152-26-037231","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CLINUVEL announced advancement of its VLRX-L controlled-release injectable peptide platform following promising preclinical results, with candidate formulations selected for further preclinical studies in Q1 2027 and manufacturing scale-up being scoped. This is a material operational/R\u0026D milestone disclosing progress on a key platform technology, but does not fit discrete event categories (not an earnings release, M\u0026A, impairment, or litigation); it is a strategic product-development update that would affect investor assessment of the company's pipeline and technical capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:08:11.489520+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28292,"accession_number":"0001493152-26-037231","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CLINUVEL announced advancement of its VLRX-L controlled-release injectable peptide platform following promising preclinical results, with candidate formulations selected for further preclinical studies in Q1 2027 and manufacturing scale-up being scoped. This is a material operational/R\u0026D milestone disclosing progress on a key platform technology, but does not fit discrete event categories (not an earnings release, M\u0026A, impairment, or litigation); it is a strategic product-development update that would affect investor assessment of the company's pipeline and technical capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:08:11.489520+00:00","company_name":"Clinuvel Pharmaceuticals Ltd","ticker":null,"filing_date":"2026-08-12"}]}